<DOC>
	<DOCNO>NCT00405210</DOCNO>
	<brief_summary>The purpose trial determine effective dose BAy 46-9003 associate taxotere first-line treatment patient prostatic cancer . BAY 43-9006 ( SORAFENIB ) novel dual-action Raf kinase VEGFR inhibitor , orally available favorable safety profile patient advance solid tumor . This , together antitumor activity observe treatment BAY 43-9006 ( SORAFENIB ) , provide rationale evaluation patient advance cancer . The recommend dose BAY 43-9006 ( SORAFENIB ) future study 400 mg bid continuous dosing schedule .</brief_summary>
	<brief_title>Pharmacokinetic Study BAY43-9006 Taxotere Treat Patient With Prostatic Cancer</brief_title>
	<detailed_description>This study propose treat patient metastatic hormone-refractory prostatic cancer first intention . There limit age 18 year old . A new inhibitor angiogenesis ( Sorafenib ) associate standard treatment type pathology . Patients demonstrate radiologically disease progression also progression base increase psa level . The main objective Determine recommend dose BAY 43-9006 combination docetaxel hormone-refractory prostate cancer patient first line treatment patient metastatic hormone-refractory prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Signed informed consent prior begin protocol specific procedure . 18 year Radiologically proven presence metastasis Histologically/cytologically proven prostate adenocarcinoma . Biochemically evaluable disease Patients must receive prior hormonal therapy define : Castration orchiectomy and/or LHRH agonist without Antiandrogens Other hormonal agent ( e.g. , ketoconazole , ... ) The testosterone level &lt; 50 ng/dl ( 10 ) document disease progression define PSA increase . Patients must value least 5 ng/ml addition increase PSA eligible . Life expectancy &gt; 3 month ECOG performance status 02 . Normal cardiac function . Prior chemotherapy except estramustine phosphate . Prior isotope therapy ( e.g. , strontium , samarium ) . Prior radiotherapy &gt; 25 % bone marrow Prior therapy antiVEGF therapy Prior malignancy except follow : adequately treat basal cell squamous cell skin cancer , cancer patient diseasefree &gt; 5 year . History presence central nervous system ( CNS ) disease ( i.e . primary brain tumor , malignant seizure , CNS metastases carcinomatous meningitis ) Symptomatic peripheral neuropathy Other serious illness medical condition use corticosteroid . Concurrent treatment experimental drug . Participation another clinical trial investigational drug within 30 day prior study screen . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption BAY 9006 . Major surgery 4 week study entry Autologous bone marrow transplant stem cell rescue within 4 month study entry Use biologic response modifier , GCSF , within 3 week study entry Treatment anticancer therapy ( except LHRH agonist ) include prescribed compound and/or OTC product treatment prostate cancer must stop . Treatment drug metabolize cytochrome P450 system ( i.e warfarin sodium , … ) Treatment systemic corticosteroid use reason specify protocol must stop . Biphosphonates could initiate inclusion protocol . At inclusion , patient receive biphosphonates PSA progression could continue biphosphonates . Patients reproductive potential employ effective method birth control . Barrier contraceptives must use throughout trial . Inadequate recovery previous surgery , radiation , chemo , biologic immunotherapy Patients know hypersensitivity study medication Substance abuse , medical social , psychological condition may interfere subject 's participation study evaluation study result Patients unable sallow oral medication .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>hormone-resistant</keyword>
	<keyword>metastatic prostatic cancer</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>naïve patient</keyword>
</DOC>